The multicenter observational clinical trial evaluating clinical efficacy of Sulperazon (cefoperazone with sulbactam)followed 203 patients with severe and nosocomial infectious complications.Majority of the patients were admitted to the intensive care unit (79.8%).The therapy was successful in 80.3%with maximum efficacy in abdominal infections (91.9%).The lowest treatment efficacy was noted in the patients with sepsis (72.5%)and bronchopneumonia (76.4%).The most frequent treatment regime was 2x2 g i.v.in 24 hours for 10 days (median).The adverse effects were not in any case indication for the interruption of the treatment.Ventilatory support,pneumonia,incorrect initial choice of antibiotic and higher number of given antibiotics were significant risk factors for the failure of antibiotic therapy.Sulperazon was assessed as well tolerated antibiotics with excellent clinical efficacy mainly in abdominal infections with negligible adverse effects.

        Key words: Sulperazon –treatment success –treatment failure